Introduction
The targeting of therapeutic genes to the liver is of particular importance for the treatment of a wide variety of diseases (reviewed in Ref. 1) . Considerable advances have been made in the ability to direct transducing viruses to the liver using a variety of strategies. 2 Retroviruses, adenoviruses and adenovirus-associated virus 3 have all been used to deliver genes to the liver. Most of these systems have relied on various viral promoters for expression of the transduced gene. This has led to limited levels of gene expression, a lack of tissue specificity, and problems with the long-term persistence of expression. Hepatic expression of the CMV promoter has been shown to be limited when incorporated into an adenoviral vector, 4 as was expression in an AAV vector in adult mice, although some expression in newborn mice was observed.
5 CMV repression appears to be at the level of gene regulation as its expression can be reactivated in response to NF kappaB induction. 6 In transfected liver cells, non-liver-specific promoters such as CMV and ␤-actin produce higher levels of expression than the albumin and ␣1-antitrypsin promoters. 7 When assayed in the context of a retroviral transduction, the inclusion of natural promoters such as the ␣1-antitrypsin, albumin, PEPCK and fatty acid binding protein promoters resulted in high expression levels, with the ␣-antitrypsin promoter resulting in the greatest expression. 8 In combination with the Apo E enhancer, the ␣1-antitrypsin promoter produced even higher levels of expression during retroviral transduction in vivo. 9 Liver-specific promoters have also been assessed in the context of adenoviral transduction, where various combinations of tissue-specific regulatory elements were shown to produce sustained expression. 4 In order to develop expression vectors with optimal characteristics, we turned to promoter elements associated with one of the main targets for gene therapy, the clotting Factor IX gene. Factor IX synthesis is confined to the liver and the gene is expressed at high levels in the adult liver. Its structure is somewhat different from other strong liver-specific promoters such as albumin and ␣1-antitrypsin as it is a TATA-less promoter. 10 As a gene that is naturally expressed in the liver, it should not be subject to the type of negative regulation which suppresses viral promoters, and once introduced may be more stably expressed.
Inherited defects in the clotting Factor VIII and IX genes result in hemophilia A and B, respectively, and correction of these defects using gene therapy is a high priority. Both of these genes are normally expressed in the liver, and their protein products must be post-translationally processed and produced in significant quantities in order to be effective. The use of the natural promoters from these genes to drive their expression in gene therapy would ensure the appropriate tissue-specific expression and, possibly, appropriate levels of these factors. We have carried out extensive characterization of the Factor IX promoter in the context of understanding the basis of the Leiden form of hemophilia.
11 This is a rare form of hemophilia B in which mutations in the promoter result in a severe deficit in Factor IX production. 12 This disease is unique in that spontaneous recovery of expression occurs following puberty, leading to resolution of the disease. 13 It has been suggested that recovery is correlated with the induction of sex steroid hormones at puberty and their activation of an androgen receptor site in the proximal promoter.
14 Alternatively, we have demonstrated that a site approximately 200 nucleotides upstream of the transcription start site (site 5), plays a key role in the recovery of transcriptional activity during puberty. 11 This element was seen to be a prime regulator of the Factor IX promoter, with point mutations in this element resulting in a dramatic decrease in promoter activity. 15 The factors binding to this site were identified as C/EBP␣, a factor expressed in a limited number of tissues including liver, intestine and fat cells, and GABP␣/␤, which is a ubiquitous ets protein. Either alone, or as a multimerized site, this element is able to direct efficient transcription initiation from a heterologous promoter. Additional transcription factors which have been shown to regulate the Factor IX promoter include HNF-4, 16 the expression of which is tissue restricted, and NF-1, another ubiquitous protein.
Given the apparent dominant effect of the site 5 element on the proximal promoter, and its ability to act as a strong activator when multimerized, we tested the effect of inclusion of a site 5 multimer on the activity of the proximal promoter. Insertion of five site 5 repeats at the 5′ end of the proximal Factor IX promoter increased expression over 20-fold when assayed in the human liver line, Hep G2. The level of expression of this plasmid was higher than that mediated by the SV40 early promoter in these cells. Inclusion of site 5 repeats at both the 5′ and 3′ ends of the transcription unit had no additional effect on expression and liver specificity. A liver-specific LCR derived from the apolipoprotein E/C locus was also incorporated into the 3′ end of the transcription unit, but did not result in a significant increase in expression. Expression of the site 5 containing constructs is highly liver specific and, over the short term, does not decay as rapidly as the SV40 early promoter directed expression. 
Results
Our previous analysis of the clotting Factor IX promoter has characterized an upstream element which has a dominant effect on the expression of this promoter. This element is referred to as site 5, and is comprised of both C/EBP␣ and GABP␣/␤ binding elements. 15 It appears to play a role in the recovery of Factor IX expression in the Leiden form of hemophilia B.
11 This type of hemophilia is the result of a variety of mutations in the proximal promoter. The importance of interactions between site 5 and elements in the proximal promoter suggested that increasing site 5 function could lead to greater promoter activity. This was done by cloning multimerized site 5 elements at the 5′ end of the proximal promoter ( Figure 1 ). By increasing the local concentration of a site and allowing both physical and functional co-operativity, multimerization often produces optimal transcriptional activity of a given site. The transcriptional activity of the wild-type Factor IX promoter (FIX) and the site 5 multimer (GTV) were tested by transient transfection into the human hepatocellular carcinoma cell line, Hep G2. This line was chosen as it has served as an in vitro model of liver specificity, and while it does not exhibit all of the characteristics of differentiated liver cells it expresses many essential liver-specific transcription factors. An SV40 enhancer/promoter construct was used for comparison as SV40 expression shows little tissue specificity and expression in the mouse liver has been shown to be robust when incorporated into an adenovirus vector. 17 Inclusion of the site 5 elements increased expression of the promoter by a factor of 20-to 35-fold, depending upon the individual transfection ( Figure 2 ). The absolute activity of the GTV construct was higher than that of a comparable amount of an SV40 enhancer/early promoter reporter (pGL2-CTRL), which is considered to be a highly active promoter. The effect of including an additional site 5 multimer at the 3′ end of the transcription unit (GTV-1) was also assessed. Its expression was comparable to that of the GTV construct, indicating that additional site 5 repeats in this region of the construct had no effect.
Locus control regions (LCR) often act to overcome the repressive effect of the chromatin environment. 18 A liverspecific LCR was introduced into the GTV construct in order to determine if the inclusion of such an element had a positive effect on transient expression of these promoters. The LCR was derived from the apolipoprotein E/C locus which has previously been shown to contain a compact LCR. 19, 20 This approximately 300 base-pair region was PCR amplified and cloned into the 3′ end of the GTV construct to generate the GTV-HCR plasmid ( Figure 1 ). This promoter exhibited slightly higher activity than the GTV construct, but the additional increase was modest, although statistically significant.
The tissue specificity of these constructs was then measured. The Factor IX gene is expressed exclusively in the liver, and this specificity is likely due to the limited tissue range of some of the factors which interact with the promoter. 21 The liver-enriched factor C/EBP␣ interacts with both site 1 and site 5, while the liver-enriched factor HNF-4 binds to site 3. These constructs were tested for their activity in the human breast cell line T-47D. All of the Factor IX constructs exhibited minimal activity in this cell line, particularly in comparison with the SV40 early promoter, which generally functions in all cell types ( Figure 3) . The GTV-HCR construct again exhibited slightly higher activity compared with the other Factor IX constructs, however the SV40 promoter was 10-fold more active in these cells. These constructs were also assayed in a mouse pre-myoblast cell line C 2 C 12 . Again, all of the Factor IX constructs exhibited minimal activity, with the SV40 promoter being at least five times more active (Figure 4) .
Part of the rationale for using the Factor IX promoter as a regulatory sequence is that the differentiated liver is clearly a conducive environment for the expression of this gene. Even though Hep G2 cells appear to synthesize small amounts of Factor IX gene, we expected that expression of the Factor IX promoter might be more persistent than that of viral promoters. Examining the expression of these plasmids over a 21 day period indicates that the activity of the Factor IX promoters does not fall off as rapidly as that of the SV40 early promoter ( Figure 5 ). Promoters containing the site 5 multimer exhibit approximately a 2.8-fold decrease in activity between 2 days and 7 days after transfection. In contrast, the Factor IX promoter alone decreases by a factor of five during this same period, and the SV40 promoter decreases by a factor of almost 10. All of the Factor IX promoters exhibited a rapid decrease in activity between day 7 and day 10, but were sustained at a lower level of activity until the end of the experiment. Inclusion of the site 5 element thus appears to augment at least the short-term persistence of expression.
While Hep G2 cells represent a well characterized model system of the human liver, their pattern of gene expression is characteristic of fetal, rather than adult liver. This is reflected in their expression of ␣-fetoprotein rather than albumin, and reduced levels of liver-enriched transcription factors such as C/EBP␣ 22 and HNF-1. Several C/EBP␣ sites appear to be critical for the function of the Factor IX promoter as well as for site 5. In order to determine if the presence of additional C/EBP␣ in these cells could augment expression of the Factor IX promoter, a C/EBP␣ expression vector was co-transfected with the various constructs. C/EBP␣ was unable to increase the expression of the Factor IX promoter ( Figure 6 ). Co-transfection of expression vectors for DBP and HLF, which have been shown to increase Factor IX promoter activity in the Leyden mutants, were also used in conjunction with C/EBP␣. This produced a slight increase in expression (data not shown), but the effect was less than two-fold. There was no significant increase in the pGL2 control plasmid in response to any of the co-transfection experiments. These results suggest that C/EBP␣ levels are not a limiting factor for the expression of Factor IX in Hep G2 cells. However, changes in other transcription factors, as well as alterations in the transcriptional machinery associated with differentiation may result in increased expression of these vectors in vivo.
Discussion
Due to the inability to transduce all target cells in the liver, the expression of therapeutic genes must be augmented to achieve therapeutic and optimally, physiological levels of protein synthesis. In order to further augment the activity of the Factor IX promoter, while maintaining some of the interactions which produce opti- Figure 2 . mal liver expression, one of the upstream transcriptional elements was multimerized and cloned upstream of the proximal promoter. The presence of the site 5 multimer had a significant effect on expression, resulting in at least a 20-fold increase in transcriptional activity. This increased the activity of the promoter in Hep G2 cells to a level greater than that directed by the SV40 early promoter, which is generally considered to be a strong promoter. Comparison of the activities of the SV40 and CMV promoters in Hep G2 cells indicates that the CMV promoter is generally about 2.5 times more active (data not shown). This indicates that the Factor IX constructs can approach the activity of even the most active viral promoters. The site 5 element has previously been shown to have a dominant effect on promoter function, as a point mutation in this element results in a dramatic loss of expression. 15 In addition, either a single copy, or a multimer of the site 5 element was able to direct efficient expression from a minimal promoter construct consisting of the albumin TATA box as its sole other transcriptional element either in transfection or as measured by in vitro transcription assays with adult rat liver nuclear extracts. 20 Previous attempts to augment liver-specific expression using a natural liver-specific promoter have mostly used the ␣1-antitrypsin promoter. 8 When combined with a liver-specific enhancer derived from the apolipoprotein E locus it was capable of directing high levels of expression in the context of retroviral transduction. 9 Recent efforts to produce an optimal promoter for muscle expression using shuffling of a wide variety of promoter elements resulted in only an eight-fold increase in promoter activity over the starting construct. 23 Using a directed approach we have been able to produce a 20-fold increase over the Factor IX promoter alone.
Figure 6 Effect of C/EBP␣ co-transfection on expression. A C/EBP␣ expression vector (MSV-C/EBP) was co-transfected into Hep G2 cells along with the various Factor IX promoter constructs and pGL2-CTRL. The cells were analyzed 3 days after transfection and the normalized activity with (shaded bar) C/EBP␣ co-transfection and without (open bar) is shown. Results are presented as in
Promoter strength is generally considered to be a product of the efficiency with which the transcriptional machinery is recruited. This includes both TFIID and TFIIB components but may also involve the recruitment of the pol II holoenzyme. Analysis of the contribution of each of the individual binding elements of the albumin promoter to transcriptional activity suggests that, while many of the individual binding sites are relatively active when multimerized, none are as strong as the whole promoter. 24 This also appears to hold true for the Factor IX promoter. 25 This illustrates that natural promoters have evolved to be comprised of binding sites for transcription factors which are able to optimally recruit all of the components required for regulated gene expression.
The extinguishment of transcriptional activity experienced with viral promoters appears to involve the loss of transcription initiation as illustrated by repression of the CMV promoter in the liver. 6 Induction of NF kappa B activity is able to restore expression partially, suggesting that transcriptional competence is maintained, but that the active recruitment of the transcriptional machinery is lacking. By employing a promoter which is normally expressed in the liver we hoped to preserve its transcriptional competency over an extended period. In comparison to the SV40 promoter, the Factor IX constructs did maintain their expression at a higher level, particularly at the day 7 time-point, where the activity of the SV40 promoter had decreased markedly. While the Factor IX plasmids continued to express at higher levels than SV40, there was a dramatic decrease in activity beyond 7 days after transfection and by day 14 there was no statistical difference between the GTV containing constructs and SV40. The cause for this decrease is currently being investigated. The inclusion of a liver-specific LCR element did not have a significant effect on the strength of the transcriptional activity of these constructs. This was not unexpected, as LCR elements are thought to play an antirepression role, by increasing the likelihood of expression rather than the rate or level of transcription. It was thought that the persistence of expression could have been augmented by the inclusion of the LCR, but while the persistence of expression of the site 5 containing plasmids was considerably better than the SV40 promoter, the LCR had no additional effect. Regulation of the ␤-globin locus suggests that these types of elements should be important for stabilizing expression. 18 It is possible that the introduced plasmid is not in a state that requires protection from chromatin effects or that, under the time frame we have studied, these effects have not yet become apparent.
While Hep G2 cells offer an excellent in vitro model system for liver cell expression, their lack of terminal differentiation is reflected in reduced levels of some liverenriched factors such as C/EBP␣ and HNF1 liver. This may limit the expression of some liver-specific genes. Indeed, Hep G2 cells express only limited amounts of endogenous Factor IX. C/EBP␣ binds to two sites in the proximal promoter, binding both site 1 and within site 5. The requirement of these factors for promoter activity contribute to the liver-specific expression of this promoter. Even with multimerization of site 5, which also binds the ubiquitous ets factor GABP ␣/␤, these constructs still exhibit a high level of tissue specificity as measured in a variety of cell lines. Interestingly, the inclusion of the liver-specific LCR appears to augment expression in non-liver cells. Although the effect is not large, it may be a consequence of the binding of some of the non-liver-specific factors which are known to bind to this LCR. Complementation with C/EBP␣, DBP and HLF did not have an effect on expression, suggesting that these factors are not directly limiting in Hep G2 cells. However, the induction of other factors which occurs as liver cells differentiate, as well as changes in the transcriptional machinery, would likely result in higher expression levels for these Factor IX constructs in the liver and possibly lead to an increase in their persistence.
The Factor IX promoter offers several advantages as part of a liver-specific gene therapy vector. As discussed above, it is able to direct high levels of expression while maintaining its intrinsic tissue specificity. Also, it is extremely compact, at only 450 bp for the most active construct it may be of particular utility in vectors with a limited carrying capacity such as retroviruses and AAV. In addition, certain aspects of its regulation suggest it may be more suitable for the treatment of children. The site 5 element site has been implicated in the recovery of promoter function which occurs following puberty in the Leiden form of hemophilia. 11 This developmental regulation of the defective Factor IX promoter suggests that in children, liver-specific expression may be controlled differently than in adults. This is supported in animal models, where the CMV promoter in an AAV vector was active in newborn but not adult mice. 5 This may be the result of the initiation of a diurnal metabolic cycle at puberty 11 or with changes in sex hormone regulation. 14 The ability of site 5 activity to complement mutations in any of three proximal promoter binding elements suggests that site 5 plays a dominant role in promoter regulation. By introducing a site 5 multimer into the promoter we would expect these constructs to function optimally in children, maintain their tissue specificity, and operate at near physiological levels.
Materials and methods

Plasmids
The Factor IX proximal promoter construct FIX has been previously described and consists of sequences from nt −219 to +21, with XhoI and HindIII sites located at the 5′ and 3′ ends, respectively. This segment is cloned into the pGL2 luciferase reporter plasmid using these sites. The site 5 oligomeric repeat has also been previously described and contains five copies of the site 5 sequence. In order to clone it into the FIX construct, synthetic primers corresponding to sequences flanking the repeat were synthesized and used to PCR amplify the multimer region. These primers incorporated KpnI and XhoI sites at opposite ends, allowing insertion into the FIX plasmids using these restriction sites: GTV3 5′-CCGGTACC TGCGGCCGCTGCTGACATAACATCCGGGGATCAGG; GTV4 5′-CCTCGAGGCAGGTCGATCC. This construct places the site 5 oligomers in the opposite orientation in relation to the promoter. The GTV-1 construct places an additional site 5 repeat at the 3′ end of the transcription unit. This was done by cleavage of the GTV construct with XhoI, cleaving adjacent to the site 5 repeat, and filling in the first two bases of the XhoI site. The site 5 repeat was then released by cleavage at the upstream side with SmaI. This fragment was then cloned into the GTV vector at the SalI and BamHI site after the complete fill in of the SalI site and a 2 base pair fill-in of the BamHI site. This construct places the 3′ site 5 repeat in the opposite orientation to that of the 5′ repeat. A minimal locus control region from the apolipoprotein E/C locus was PCR amplified using the following primers: HCR1-BAM 5′-GGGGATCCTGCAGGCTCAGA GGCACACAGG; HCR1-SAL 5′-GGGTCGACAAGTGG TTTTGAACCCGGACCC. Amplification was carried out using Vent polymerase (New England Biolabs, Mississauga, Canada) according to the manufacturer's conditions. This 344 base pair fragment which has been shown to have liver-specific LCR function, was then cloned at the 3′ end of the GTV construct using the BamHI and SalI sites. Sequencing was used to confirm the structure of all of the plasmid constructs.
Cell culture and transfection Hep G2, T47D and C 2 C 12 cells were obtained from the ATCC (Rockland, MD, USA) and were grown in MEM, RPMI and DMEM, respectively, containing 10% fetal bovine serum with the addition of penicillin and streptomycin. Cell transfection was carried out using FuGene 6 carrier (Boehringer Mannheim, Montreal, Canada) according to the manufacturer's instructions. Generally, 2 g of plasmid DNA was complexed with 2 l of FuGene and applied to a six-well plate containing 2 ml of medium per well. Normally, 100 ng of the pRL-SV40 renilla luciferase gene was added as an internal control. The pGL2-CTRL plasmid (Promega, Madison, WI, USA) which contains the SV40 early promoter and enhancer was used for comparison with the Factor IX constructs. The pGL2-CTRL construct has an otherwise identical backbone to the Factor IX plasmids. In co-transfection experiments MSV-C/EBP, CMV-DBP or XMHLFsRI were added at 100 ng per transfection. Luciferase assays (luciferase and renilla) were carried out using the Promega Dual Luciferase kit, according to the manufacturer's instructions except that 50 l of each assay reagent was used per sample. All experiments were carried out with three completely independent samples.
